• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

Managing Atopic Dermatitis Treatment Escalation in Pregnancy: Considerations and Approaches

Author(s):

Elizabeth Kiracofe, MD, FAAD,Jenny Murase, MD, FAAD

Drs Kiracofe and Murase provide clinical insights on treatment escalation practices for patients with atopic dermatitis who are pregnant.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Nickel is the Most Prevalent Allergen in Pediatric Patients With and Without Atopic Dermatitis
January 27th 2025

Nickel is the Most Prevalent Allergen in Pediatric Patients With and Without Atopic Dermatitis

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Limited Evidence Supporting the Efficacy of Antifungals for Atopic Dermatitis
January 17th 2025

Limited Evidence Supporting the Efficacy of Antifungals for Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Nutrition, Obesity, and Anxiety Can Impact the Severity of Seborrheic Dermatitis
January 15th 2025

Nutrition, Obesity, and Anxiety Can Impact the Severity of Seborrheic Dermatitis

LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases
January 13th 2025

LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases

© 2025 MJH Life Sciences

All rights reserved.